Esperion Therapeutics Stock Performance
| ESPR Stock | USD 2.57 0.05 1.98% |
On a scale of 0 to 100, Esperion Therapeutics holds a performance score of 12. The firm shows a Beta (market volatility) of 1.96, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Esperion Therapeutics will likely underperform. Please check Esperion Therapeutics' value at risk, as well as the relationship between the kurtosis and market facilitation index , to make a quick decision on whether Esperion Therapeutics' price patterns will revert.
Risk-Adjusted Performance
12 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Esperion Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating basic indicators, Esperion Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.97 | Five Day Return 8.58 | Year To Date Return (11.13) | Ten Year Return (91.85) | All Time Return (82.10) |
Last Split Factor 1:6 | Last Split Date 2013-06-11 |
1 | Disposition of 2608 shares by Warren Eric of Esperion Therapeutics at 1.783 subject to Rule 16b-3 | 09/17/2024 |
2 | Esperion CEO Sheldon Koenig sells shares worth over 26k | 09/18/2024 |
3 | Disposition of 107 shares by Warren Eric of Esperion Therapeutics at 2.119 subject to Rule 16b-3 | 10/17/2024 |
4 | Esperion Therapeutics May Report Negative Earnings Know the Trend Ahead of Next Weeks Release | 10/31/2024 |
5 | Vanguard Group Incs Strategic Acquisition in Esperion Therapeutics Inc | 11/05/2024 |
6 | Esperions Q3 Loss Wider Than Expected, Revenues Rise YY | 11/07/2024 |
7 | Esperion Therapeutics Inc Q3 2024 Earnings Call Highlights Strong Revenue Growth Amidst ... | 11/08/2024 |
8 | Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL in Oral Featured Science Session and Multiple Poster Presentat... | 11/18/2024 |
9 | Disposition of 197 shares by Warren Eric of Esperion Therapeutics at 2.165 subject to Rule 16b-3 | 11/19/2024 |
10 | Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference | 11/21/2024 |
| Begin Period Cash Flow | 124.8 M |
Esperion |
Esperion Therapeutics Relative Risk vs. Return Landscape
If you would invest 170.00 in Esperion Therapeutics on August 28, 2024 and sell it today you would earn a total of 87.00 from holding Esperion Therapeutics or generate 51.18% return on investment over 90 days. Esperion Therapeutics is currently generating 0.7618% in daily expected returns and assumes 4.6396% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Esperion, and 85% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Esperion Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Esperion Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Esperion Therapeutics, and traders can use it to determine the average amount a Esperion Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1642
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ESPR | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.64 actual daily | 41 59% of assets are more volatile |
Expected Return
| 0.76 actual daily | 15 85% of assets have higher returns |
Risk-Adjusted Return
| 0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average Esperion Therapeutics is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Esperion Therapeutics by adding it to a well-diversified portfolio.
Esperion Therapeutics Fundamentals Growth
Esperion Stock prices reflect investors' perceptions of the future prospects and financial health of Esperion Therapeutics, and Esperion Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Esperion Stock performance.
| Return On Equity | -2.61 | ||||
| Return On Asset | 0.0384 | ||||
| Profit Margin | (0.29) % | ||||
| Operating Margin | (0.31) % | ||||
| Current Valuation | 630.63 M | ||||
| Shares Outstanding | 197.04 M | ||||
| Price To Earning | (8.19) X | ||||
| Price To Book | 98.42 X | ||||
| Price To Sales | 1.71 X | ||||
| Revenue | 116.33 M | ||||
| Gross Profit | (70.42 M) | ||||
| EBITDA | (150.11 M) | ||||
| Net Income | (209.25 M) | ||||
| Cash And Equivalents | 185.84 M | ||||
| Cash Per Share | 2.79 X | ||||
| Total Debt | 540.95 M | ||||
| Current Ratio | 3.07 X | ||||
| Book Value Per Share | (1.89) X | ||||
| Cash Flow From Operations | (135.49 M) | ||||
| Earnings Per Share | (0.67) X | ||||
| Market Capitalization | 506.38 M | ||||
| Total Asset | 205.8 M | ||||
| Retained Earnings | (1.55 B) | ||||
| Working Capital | 44.84 M | ||||
| Current Asset | 214.39 M | ||||
| Current Liabilities | 5.62 M | ||||
About Esperion Therapeutics Performance
Assessing Esperion Therapeutics' fundamental ratios provides investors with valuable insights into Esperion Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Esperion Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 553.60 | 525.92 | |
| Return On Tangible Assets | (1.02) | (1.07) | |
| Return On Capital Employed | (3.14) | (2.98) | |
| Return On Assets | (1.02) | (1.07) | |
| Return On Equity | 0.46 | 0.48 |
Things to note about Esperion Therapeutics performance evaluation
Checking the ongoing alerts about Esperion Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Esperion Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Esperion Therapeutics appears to be risky and price may revert if volatility continues | |
| Esperion Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 116.33 M. Net Loss for the year was (209.25 M) with loss before overhead, payroll, taxes, and interest of (70.42 M). | |
| Esperion Therapeutics currently holds about 185.84 M in cash with (135.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Esperion Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Roughly 66.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference |
- Analyzing Esperion Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Esperion Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Esperion Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Esperion Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Esperion Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Esperion Therapeutics' stock. These opinions can provide insight into Esperion Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.